CoChat

Analytical variability in the determination of anti-double-stranded DNA antibodies: the strong need of a better definition of the old and new tests

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Abstract

Anti-dsDNA antibodies are a heterogeneous group of antibodies, quite specific for SLE. Their variability is related to the assay used, the immunoglobulin class secondary antibody, and the dsDNA source. The standardization of measuring anti-dsDNA antibodies is still poor and different methods yield different results. Several novel technologies were developed during the last decades that represent viable alternatives to the traditional methods such as the chemiluminescent immunoassay (CIA) and multiplex flow immunoassay (MFI). Additionally, positive results for anti-dsDNA antibodies can be detected in patients with inflammatory arthritis (IA) treated with different biologics reducing its clinical specificity for SLE. Anti-dsDNA antibody levels were evaluated in 246 patient samples: 70 SLE and 176 disease control (including 96 IA during treatment with different biologics), using three enzyme immunoassays (indirect enzyme immunoassay, Bio-Rad Laboratories; chemiluminescent immunoassay, Inova Diagnostics; multiplex flow immunoassay, Bio-Rad Laboratories) and three Crithidia luciliae immunofluorescence tests (CLIFT) (Euroimmun AG, Bio-Rad Laboratories, INOVA Diagnostics). Diagnostic performances were assessed both including and excluding the IA patients. Agreements, measured by the Cohen's Kappa between all methods, ranged from moderate to substantial (0.47-0.68). The clinical sensitivities for the anti-dsDNA antibody tests varied from 5.7% by CLIFT A up to 33.3% provided by EIA wh…

Overview

Integrity signals

Registry

Crossref · 10.1007/s12026-018-8992-9

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

8 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 42 references

Research works printed but not linked: 1

  1. Hillebrand JJ, Bernelot Moens HJ, Mulder AH. Changes in Farr radioimmunoassay and EliA fluorescence immunoassay anti-dsDNA in relation to exacerbation of SLE. Lupus. 2013;22:1169–73. · DOI · Paper page

Cited by

See all 19

Metadata

Authors
Infantino, M., Manfredi, M., Merone, M., Grossi, V., Benucci, M., Li Gobbi, F., Bandinelli, F., Damiani, A., & Soda, P.
Affiliations
  • Nuovo Ospedale San Giovanni di Dio (IT)
  • Università Campus Bio-Medico (IT)
Corresponding author
Infantino, Maria
Venue
Immunologic Research
Published
2018-04-05
Volume
66
Issue
3
Pages
340-347
ISSN
  • 0257-277X (ISSN-L)
  • 1559-0755
OpenAlex
W2795412599
Cited by
16
References
42
Citations by year
2026: 1 · 2025: 2 · 2024: 3 · 2023: 2 · 2022: 2 · 2021: 5 · 2020: 1
FWCI
1.29
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Immunologic Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
  • Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
  • Health Sciences › Health Professions › Medical Laboratory Technology › Clinical Laboratory Practices and Quality Control
Keywords
anti-dsDNA antibodies, systemic lupus erythematosus, assay standardization, analytical variability, inflammatory arthritis, biologic therapy, chemiluminescence immunoassay, indirect enzyme immunoassay, sensitivity and specificity, assay agreement
MeSH terms
Antibodies, Antinuclear, Arthritis, Rheumatoid, Crithidia, DNA, Fluorescent Antibody Technique, Humans, Immunoassay, Luminescent Measurements, Lupus Erythematosus, Systemic, Sensitivity and Specificity, Reproducibility of Results

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Analytical variability in the determination of anti-double-stranded DNA antibodies: the strong need of a better definition of the old and new tests. https://app.cochat.ai/papers/10.1007/s12026-018-8992-9
The paper
Infantino, M., Manfredi, M., Merone, M., Grossi, V., Benucci, M., Li Gobbi, F., Bandinelli, F., Damiani, A., & Soda, P. (2018). Analytical variability in the determination of anti-double-stranded DNA antibodies: the strong need of a better definition of the old and new tests. Immunologic Research. https://doi.org/10.1007/s12026-018-8992-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.